Cyproheptadine prevents the initial occurence of successive negative contrast

Patricia S. Grigson, Charles F. Flaherty

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Rats shifted from 32% to 4% sucrose make fewer licks for 4% sucrose than rats having only experienced the lower reward. In Experiment 1, the occurrence of this contrast effect was prevented by the administration of the nonspecific serotonin antagonist cyproheptadine (3.0 or 6.0 mg/kg). The results of Experiments 2 and 3 demonstrated that the contrast-reducing action of cyproheptadine was not mediated by the antiserotonergic properties of the drug since systemic administration of the serotonin synthesis inhibitor, PCPA (150 or 300 mg/kg), failed to influence either the occurence of contrast or the attenuation of contrast by cyproheptadine. The results of Experiment 4 indicated that the contrast-reducing action of cyproheptadine was not mediated by the antihistaminergic properties of the drug since the antihistamine, pyrilamine (6 or 12 mg/kg), also failed to prevent the occurence of contrast. Finally, the contrast-reducing action of cyproheptadine was not due to rate-dependent and/or appetite stimulating effects since cyproheptadine did not serve to increase lick frequency in rate-dependent controls.

Original languageEnglish (US)
Pages (from-to)433-442
Number of pages10
JournalPharmacology, Biochemistry and Behavior
Volume40
Issue number2
DOIs
StatePublished - Oct 1991

Fingerprint

Cyproheptadine
Sucrose
Rats
Pyrilamine
Serotonin Antagonists
Histamine Antagonists
Experiments
Appetite
Reward
Pharmaceutical Preparations
Serotonin

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

@article{00a36e203f254b12b2c21373d37df744,
title = "Cyproheptadine prevents the initial occurence of successive negative contrast",
abstract = "Rats shifted from 32{\%} to 4{\%} sucrose make fewer licks for 4{\%} sucrose than rats having only experienced the lower reward. In Experiment 1, the occurrence of this contrast effect was prevented by the administration of the nonspecific serotonin antagonist cyproheptadine (3.0 or 6.0 mg/kg). The results of Experiments 2 and 3 demonstrated that the contrast-reducing action of cyproheptadine was not mediated by the antiserotonergic properties of the drug since systemic administration of the serotonin synthesis inhibitor, PCPA (150 or 300 mg/kg), failed to influence either the occurence of contrast or the attenuation of contrast by cyproheptadine. The results of Experiment 4 indicated that the contrast-reducing action of cyproheptadine was not mediated by the antihistaminergic properties of the drug since the antihistamine, pyrilamine (6 or 12 mg/kg), also failed to prevent the occurence of contrast. Finally, the contrast-reducing action of cyproheptadine was not due to rate-dependent and/or appetite stimulating effects since cyproheptadine did not serve to increase lick frequency in rate-dependent controls.",
author = "Grigson, {Patricia S.} and Flaherty, {Charles F.}",
year = "1991",
month = "10",
doi = "10.1016/0091-3057(91)90576-N",
language = "English (US)",
volume = "40",
pages = "433--442",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "2",

}

Cyproheptadine prevents the initial occurence of successive negative contrast. / Grigson, Patricia S.; Flaherty, Charles F.

In: Pharmacology, Biochemistry and Behavior, Vol. 40, No. 2, 10.1991, p. 433-442.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyproheptadine prevents the initial occurence of successive negative contrast

AU - Grigson, Patricia S.

AU - Flaherty, Charles F.

PY - 1991/10

Y1 - 1991/10

N2 - Rats shifted from 32% to 4% sucrose make fewer licks for 4% sucrose than rats having only experienced the lower reward. In Experiment 1, the occurrence of this contrast effect was prevented by the administration of the nonspecific serotonin antagonist cyproheptadine (3.0 or 6.0 mg/kg). The results of Experiments 2 and 3 demonstrated that the contrast-reducing action of cyproheptadine was not mediated by the antiserotonergic properties of the drug since systemic administration of the serotonin synthesis inhibitor, PCPA (150 or 300 mg/kg), failed to influence either the occurence of contrast or the attenuation of contrast by cyproheptadine. The results of Experiment 4 indicated that the contrast-reducing action of cyproheptadine was not mediated by the antihistaminergic properties of the drug since the antihistamine, pyrilamine (6 or 12 mg/kg), also failed to prevent the occurence of contrast. Finally, the contrast-reducing action of cyproheptadine was not due to rate-dependent and/or appetite stimulating effects since cyproheptadine did not serve to increase lick frequency in rate-dependent controls.

AB - Rats shifted from 32% to 4% sucrose make fewer licks for 4% sucrose than rats having only experienced the lower reward. In Experiment 1, the occurrence of this contrast effect was prevented by the administration of the nonspecific serotonin antagonist cyproheptadine (3.0 or 6.0 mg/kg). The results of Experiments 2 and 3 demonstrated that the contrast-reducing action of cyproheptadine was not mediated by the antiserotonergic properties of the drug since systemic administration of the serotonin synthesis inhibitor, PCPA (150 or 300 mg/kg), failed to influence either the occurence of contrast or the attenuation of contrast by cyproheptadine. The results of Experiment 4 indicated that the contrast-reducing action of cyproheptadine was not mediated by the antihistaminergic properties of the drug since the antihistamine, pyrilamine (6 or 12 mg/kg), also failed to prevent the occurence of contrast. Finally, the contrast-reducing action of cyproheptadine was not due to rate-dependent and/or appetite stimulating effects since cyproheptadine did not serve to increase lick frequency in rate-dependent controls.

UR - http://www.scopus.com/inward/record.url?scp=0026317666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026317666&partnerID=8YFLogxK

U2 - 10.1016/0091-3057(91)90576-N

DO - 10.1016/0091-3057(91)90576-N

M3 - Article

C2 - 1839569

AN - SCOPUS:0026317666

VL - 40

SP - 433

EP - 442

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 2

ER -